News

Announcements 13 September 2021

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1...

Houston, TX, and Singapore, September 13, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies...

Announcements 01 September 2021

Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief...

Houston, TX, and Singapore, September 1, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies...

Announcements 02 August 2021

Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of...

– HMBD-001 is the first clinical stage asset generated by Hummingbird’s proprietary Rational Antibody Discovery (RAD) platform Houston and Singapore,...

Announcements 26 July 2021

Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch...

Houston and Singapore, July 26, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against...

Announcements 12 July 2021

Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration to Advance Innovative...

– Multi-year collaboration will investigate and evaluate Hummingbird’s HMBD-002 VISTA antagonist antibody Houston and Singapore, July 12, 2021 – Hummingbird...

Announcements 15 June 2021

Hummingbird Bioscience to Speak at 2021 Virtual Symposium: “VISTA: A New Immune...

Houston, TX, and Singapore, June 14, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies...

Announcements 09 June 2021

Hummingbird Bioscience and Novogene enter into strategic partnership to expand precision medicine...

-- Partnership will enhance biomarker-driven patient enrollment in clinical trials of Hummingbird Bioscience’s lead program, HMBD-001 Houston, TX, and Singapore,...

Announcements 31 May 2021

Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the...

- HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development- HMBD-002 is anticipated to enter a Phase 1...